Table 3.
Distribution of patients by minimal residual disease level measured at the end of induction stratified by clinical characteristics, treatment, and genetic features
| Low minimal residual disease (n=82) | High minimal residual disease (n=110) | p value* | |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 10·33 (3·16) | 10·29 (3·60) | .. |
| Median (IQR) | 10·08 (6·58–12·17) | 9·33 (7·25–13·08) | 0·68 |
| Sex | |||
| Women | 38 (46%) | 48 (44%) | 0·71 |
| Men | 44 (54%) | 62 (56%) | .. |
| Drug | |||
| Mitoxantrone | 63 (77%) | 84 (76%) | 0·94 |
| Idarubicin | 19 (23%) | 26 (24%) | .. |
| Single site | |||
| Isolated bone marrow | 66 (80%) | 91 (83%) | 0·59 |
| Bone marrow with CNS | 7 (9%) | 12 (11%) | .. |
| Bone marrow with testes or skin | 9 (11%) | 7 (6%) | .. |
| Combined sites | |||
| Isolated bone marrow | 66 (80%) | 91 (83%) | 0·69 |
| Combined bone marrow | 16 (20%) | 19 (17%) | .. |
| Cytogenetic risk | |||
| Standard | 56 (71%) | 59 (57%) | 0·12 |
| Intermediate | 20 (25%) | 36 (35%) | .. |
| High | 3 (4%) | 9 (9%) | .. |
| UKALL CNA profile | |||
| Good risk | 25 (48%) | 30 (39%) | 0·33 |
| Intermediate or poor risk | 27 (52%) | 46 (61%) | .. |
| Deletions or mutations | |||
| IKZF1 | 9 (17%) | 21 (28%) | 0·18 |
| NR3C1 | 1 (3%) | 6 (8%) | 0·18 |
| PAX5 | 7 (13%) | 17 (22%) | 0·21 |
| IKZF1/PAX5/NR3C1 | 13 (24%) | 33 (41%) | 0·039 |
| CDKN2A/B | 18 (35%) | 25 (33%) | 0·91 |
| ETV6 | 11 (21%) | 11 (14%) | 0·33 |
| TP53 | 5 (8%) | 6 (7%) | 0·74 |
| P2RY8-CRLF2 | 4 (8%) | 6 (8%) | 1 |
| NRAS | 5 (9%) | 7 (10%) | 0·92 |
| KRAS | 7 (13%) | 7 (10%) | 0·58 |
| IKZF1/PAX5/NR3C1/NRAS | 16 (29%) | 36 (44%) | 0·060 |
Patients without minimal residual disease measured at timepoint 1 were excluded. High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. CNA=copy number alteration.
*
p value for χ2, Fisher's exact test, or Mann-Whitney U test.